Back to results

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

Primary Purpose

Neovascular Age-related Macular Degeneration

Status

Terminated

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

0.5 mg Conbercept Intravitreal Injection

1.0 mg Conbercept Intravitreal Injection

2.0 mg Aflibercept Intravitreal Injection

About this trial

This is an interventional treatment trial for Neovascular Age-related Macular Degeneration

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Men and women ≥ 50 years of age at the Screening visit;
Females must be at least 1 year postmenopausal, or surgically sterilized, or, if of childbearing potential, must have a negative pregnancy test at the Screening visit;
o Women of childbearing potential must agree to use a highly effective method of contraception throughout the study.
Have received no previous treatment for neovascular AMD, including laser photocoagulation and/or photodynamic therapy (PDT) and/or IVT VEGF antagonists (treatment naïve) and;
Have active subfoveal choroidal neovascularization (CNV) lesions secondary to AMD (including polypoidal choroidal vasculopathy (PCV)) evidenced by subfoveal fluorescein angiography (FA) leakage, or definite subfoveal fluid by SD-OCT in the study eye at Screening;
Have a ETDRS BCVA letter score of 78 to 25 in the study eye at Screening;
Are willing and able to sign the study written informed consent form (ICF).

Exclusion Criteria:

Have had any prior ocular or systemic treatment (investigational or approved) or surgery for the treatment of neovascular AMD in the study eye except dietary supplements or vitamins;
Have participated as a subject in any interventional clinical trial within one month (30 days) prior to Baseline visit;
Have a subretinal hemorrhage that is either 50% or more of the total lesion area, or blood is under the fovea and is one or more disc areas in size (greater than 2.5 mm2) in the study eye at Screening;
Have any retinal pigment epithelial tears or rips in the study eye at Screening or upon examination at Baseline;
Have any vitreous hemorrhage in the study eye upon examination at Baseline or history of vitreous hemorrhage within eight weeks prior to Screening;
Have any other cause of CNV;
Have had prior pars plana vitrectomy in the study eye;
Have presence of a full thickness macular hole at Screening or upon examination at Baseline or a history of a full thickness macular hole in the study eye;
Have prior trabeculectomy or other filtration surgery in the study eye;
Have uncontrolled glaucoma;
Have active intraocular inflammation in either eye at Screening or upon examination at Baseline or a history of uveitis in either eye;
Have aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye;
Significant media opacities, including cataract, in the study eye that, in the opinion of the Investigator, could require either medical or surgical intervention during the study period;
Have any use of long acting intraocular steroids, including implants, within six months prior to Day 1, Baseline;
Have any known allergy to povidone iodine or known serious allergy to the fluorescein sodium for injection in angiography;
Any history of known contraindications indicated in the Food and Drug Administration (FDA)-approved label for the active control;
If female, be pregnant (positive urine pregnancy test at Screening) or breastfeeding.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Arm Label

0.5 mg Conbercept

1.0 mg Conbercept

Aflibercept

Arm Description

Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.

Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.

Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.

Outcomes

Primary Outcome Measures

Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eye

BCVA was assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) method

Secondary Outcome Measures

Proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36

To assess proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36

Proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36

To assess proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36

Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at Week 36

To assess mean change from baseline in central retinal thickness (µm) by spectral

Proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48

To assess proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48

Mean change from baseline in ETDRS BCVA letter score at Week 96

To assess mean change from baseline in ETDRS BCVA letter score at Week 96

Number of participants with adverse events as measure of safety and tolerability

To assess the number of participants with adverse events as measure of safety and tolerability

Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible

To assess the blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible

Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible

To assess half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible

Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible

To assess the presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible

Full Information

NCT ID

NCT03577899

First Posted

June 13, 2018

Last Updated

June 23, 2021

Sponsor

Chengdu Kanghong Biotech Co., Ltd.

1. Study Identification

Unique Protocol Identification Number

NCT03577899

Brief Title

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

Official Title

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)

Study Type

Interventional

2. Study Status

Record Verification Date

June 2021

Overall Recruitment Status

Terminated

Why Stopped

desired primary endpoint was not met

Study Start Date

September 25, 2018 (Actual)

Primary Completion Date

September 25, 2020 (Actual)

Study Completion Date

May 19, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Chengdu Kanghong Biotech Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.

Detailed Description

A multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial, which will randomize approximately 1140 subjects in a ratio of 1:1:1 to receive IVT injections of 0.5 mg conbercept, 1.0 mg conbercept, or 2.0 mg aflibercept. The trial includes a screening period of less than or equal to 14 days, followed by a treatment period of 92 weeks (last assessment at 96 weeks) with primary efficacy analysis at 36 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Neovascular Age-related Macular Degeneration

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

1157 (Actual)

8. Arms, Groups, and Interventions

Arm Title

0.5 mg Conbercept

Arm Type

Experimental

Arm Description

Arm Title

1.0 mg Conbercept

Arm Type

Experimental

Arm Description

Arm Title

Aflibercept

Arm Type

Active Comparator

Arm Description

Intervention Type

Biological

Intervention Name(s)

0.5 mg Conbercept Intravitreal Injection

Intervention Description

Intervention Type

Biological

Intervention Name(s)

1.0 mg Conbercept Intravitreal Injection

Intervention Description

Intervention Type

Biological

Intervention Name(s)

2.0 mg Aflibercept Intravitreal Injection

Other Intervention Name(s)

Eylea®

Intervention Description

Primary Outcome Measure Information:

Title

Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eye

Description

BCVA was assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) method

Time Frame

Baseline to Week 36

Secondary Outcome Measure Information:

Title

Proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36

Description

To assess proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36

Time Frame

Baseline to Week 36

Title

Proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36

Description

To assess proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36

Time Frame

Baseline to Week 36

Title

Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at Week 36

Description

To assess mean change from baseline in central retinal thickness (µm) by spectral

Time Frame

Baseline and Week 36

Title

Proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48

Description

To assess proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48

Time Frame

Baseline to Week 48

Title

Mean change from baseline in ETDRS BCVA letter score at Week 96

Description

To assess mean change from baseline in ETDRS BCVA letter score at Week 96

Time Frame

Baseline and Week 96

Title

Number of participants with adverse events as measure of safety and tolerability

Description

To assess the number of participants with adverse events as measure of safety and tolerability

Time Frame

Baseline to Week 96

Title

Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible

Description

To assess the blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible

Time Frame

Baseline to Week 96

Title

Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible

Description

To assess half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible

Time Frame

Baseline to Week 96

Title

Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible

Description

To assess the presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible

Time Frame

Baseline to Week 96

10. Eligibility

Sex

All

Minimum Age & Unit of Time

50 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Men and women ≥ 50 years of age at the Screening visit; Females must be at least 1 year postmenopausal, or surgically sterilized, or, if of childbearing potential, must have a negative pregnancy test at the Screening visit; o Women of childbearing potential must agree to use a highly effective method of contraception throughout the study. Have received no previous treatment for neovascular AMD, including laser photocoagulation and/or photodynamic therapy (PDT) and/or IVT VEGF antagonists (treatment naïve) and; Have active subfoveal choroidal neovascularization (CNV) lesions secondary to AMD (including polypoidal choroidal vasculopathy (PCV)) evidenced by subfoveal fluorescein angiography (FA) leakage, or definite subfoveal fluid by SD-OCT in the study eye at Screening; Have a ETDRS BCVA letter score of 78 to 25 in the study eye at Screening; Are willing and able to sign the study written informed consent form (ICF). Exclusion Criteria: Have had any prior ocular or systemic treatment (investigational or approved) or surgery for the treatment of neovascular AMD in the study eye except dietary supplements or vitamins; Have participated as a subject in any interventional clinical trial within one month (30 days) prior to Baseline visit; Have a subretinal hemorrhage that is either 50% or more of the total lesion area, or blood is under the fovea and is one or more disc areas in size (greater than 2.5 mm2) in the study eye at Screening; Have any retinal pigment epithelial tears or rips in the study eye at Screening or upon examination at Baseline; Have any vitreous hemorrhage in the study eye upon examination at Baseline or history of vitreous hemorrhage within eight weeks prior to Screening; Have any other cause of CNV; Have had prior pars plana vitrectomy in the study eye; Have presence of a full thickness macular hole at Screening or upon examination at Baseline or a history of a full thickness macular hole in the study eye; Have prior trabeculectomy or other filtration surgery in the study eye; Have uncontrolled glaucoma; Have active intraocular inflammation in either eye at Screening or upon examination at Baseline or a history of uveitis in either eye; Have aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye; Significant media opacities, including cataract, in the study eye that, in the opinion of the Investigator, could require either medical or surgical intervention during the study period; Have any use of long acting intraocular steroids, including implants, within six months prior to Day 1, Baseline; Have any known allergy to povidone iodine or known serious allergy to the fluorescein sodium for injection in angiography; Any history of known contraindications indicated in the Food and Drug Administration (FDA)-approved label for the active control; If female, be pregnant (positive urine pregnancy test at Screening) or breastfeeding.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Yan Cheng, MD, PhD

Organizational Affiliation

Chengdu Kanghong Biotechnology Co.,Ltd.

Official's Role

Study Director

Facility Information:

Facility Name

Kanghong Investigative Site

City

Phoenix

State/Province

Arizona

ZIP/Postal Code

85053

Country

United States

Facility Name

Kanghong Investigative Site

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85704

Country

United States

Facility Name

Kanghong Investigative Site

City

Beverly Hills

State/Province

California

ZIP/Postal Code

90211-1841

Country

United States

Facility Name

Kanghong Investigative Site

City

Campbell

State/Province

California

ZIP/Postal Code

95008

Country

United States

Facility Name

Kanghong Investigative Site

City

Fullerton

State/Province

California

ZIP/Postal Code

92835

Country

United States

Facility Name

Kanghong Investigative Site

City

Glendale

State/Province

California

ZIP/Postal Code

91203

Country

United States

Facility Name

Kanghong Investigative Site

City

La Jolla

State/Province

California

ZIP/Postal Code

92093

Country

United States

Facility Name

Kanghong Investigative Site

City

Mountain View

State/Province

California

ZIP/Postal Code

94040

Country

United States

Facility Name

Kanghong Investigative Site

City

Oakland

State/Province

California

ZIP/Postal Code

94609

Country

United States

Facility Name

Kanghong Investigative Site

City

Palm Desert

State/Province

California

ZIP/Postal Code

92211

Country

United States

Facility Name

Kanghong Investigative Site

City

Palm Desert

State/Province

California

ZIP/Postal Code

92260

Country

United States

Facility Name

Kanghong Investigative Site

City

Sacramento

State/Province

California

ZIP/Postal Code

95825

Country

United States

Facility Name

Kanghong Investigative Site

City

Walnut Creek

State/Province

California

ZIP/Postal Code

94598

Country

United States

Facility Name

Kanghong Investigative Site

City

Golden

State/Province

Colorado

ZIP/Postal Code

80401

Country

United States

Facility Name

Kanghong Investigative Site

City

Fort Myers

State/Province

Florida

ZIP/Postal Code

33907

Country

United States

Facility Name

Kanghong Investigative Site

City

Fort Myers

State/Province

Florida

ZIP/Postal Code

33912

Country

United States

Facility Name

Kanghong Investigative Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32224

Country

United States

Facility Name

Kanghong Investigative Site

City

Lakeland

State/Province

Florida

ZIP/Postal Code

33805

Country

United States

Facility Name

Kanghong Investigative Site

City

Ocala

State/Province

Florida

ZIP/Postal Code

34474

Country

United States

Facility Name

Kanghong Investigative Site

City

Orlando

State/Province

Florida

ZIP/Postal Code

32806

Country

United States

Facility Name

Kanghong Investigative Site

City

Plantation

State/Province

Florida

ZIP/Postal Code

33324

Country

United States

Facility Name

Kanghong Investigative Site

City

Saint Petersburg

State/Province

Florida

ZIP/Postal Code

33711

Country

United States

Facility Name

Kanghong Investigative Site

City

Sarasota

State/Province

Florida

ZIP/Postal Code

34239

Country

United States

Facility Name

Kanghong Investigative Site

City

Tampa

State/Province

Florida

ZIP/Postal Code

33617

Country

United States

Facility Name

Kanghong Investigative Site

City

'Aiea

State/Province

Hawaii

ZIP/Postal Code

96701

Country

United States

Facility Name

Kanghong Investigative Site

City

Bloomington

State/Province

Illinois

ZIP/Postal Code

61704

Country

United States

Facility Name

Kanghong Investigative Site

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60612

Country

United States

Facility Name

Kanghong Investigative Site

City

Lemont

State/Province

Illinois

ZIP/Postal Code

60439-2915

Country

United States

Facility Name

Kanghong Investigative Site

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67226-3443

Country

United States

Facility Name

Kanghong Investigative Site

City

Paducah

State/Province

Kentucky

ZIP/Postal Code

42001

Country

United States

Facility Name

Kanghong Investigative Site in MD

City

Hagerstown

State/Province

Maryland

ZIP/Postal Code

21740

Country

United States

Facility Name

Kanghong Investigative Site

City

Hagerstown

State/Province

Maryland

ZIP/Postal Code

21740

Country

United States

Facility Name

Kanghong Investigative Site

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02114

Country

United States

Facility Name

Kanghong Investigative Site

City

Detroit

State/Province

Michigan

ZIP/Postal Code

48202

Country

United States

Facility Name

Kanghong Investigator Site

City

Bloomfield

State/Province

New Jersey

ZIP/Postal Code

07003

Country

United States

Facility Name

Kanghong Investigative Site

City

Albany

State/Province

New York

ZIP/Postal Code

12206

Country

United States

Facility Name

Kanghong Investigative Site

City

Hauppauge

State/Province

New York

ZIP/Postal Code

11788

Country

United States

Facility Name

Kanghong Investigative Site

City

Rochester

State/Province

New York

ZIP/Postal Code

14620-4655

Country

United States

Facility Name

Kanghong Investigative Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45242

Country

United States

Facility Name

Kanghong Investigative Site

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44122-7344

Country

United States

Facility Name

Kanghong Investigative Site

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44195

Country

United States

Facility Name

Kanghong Investigative Site

City

Dublin

State/Province

Ohio

ZIP/Postal Code

43016

Country

United States

Facility Name

Kanghong Investigative Site

City

Eugene

State/Province

Oregon

ZIP/Postal Code

97401

Country

United States

Facility Name

Kanghong Investigative Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19107

Country

United States

Facility Name

Kanghong Investigative Site

City

West Mifflin

State/Province

Pennsylvania

ZIP/Postal Code

15122-2474

Country

United States

Facility Name

Kanghong Investigative Site

City

Nashville

State/Province

Tennessee

ZIP/Postal Code

37203-5601

Country

United States

Facility Name

Kanghong Investigative Site

City

Abilene

State/Province

Texas

ZIP/Postal Code

79606-1224

Country

United States

Facility Name

Kanghong Investigative Site

City

Katy

State/Province

Texas

ZIP/Postal Code

77494

Country

United States

Facility Name

Kanghong Investigative Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78215

Country

United States

Facility Name

Kanghong Investigative Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78240-1502

Country

United States

Facility Name

Kanghong Investigative Site in TX

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78240

Country

United States

Facility Name

Kanghong Investigative Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78240

Country

United States

Facility Name

Kanghong Investigative Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78251

Country

United States

Facility Name

Kanghong Investigator Site

City

Southlake

State/Province

Texas

ZIP/Postal Code

76902

Country

United States

Facility Name

Kanghong Investigative Site

City

The Woodlands

State/Province

Texas

ZIP/Postal Code

77384

Country

United States

Facility Name

Kanghong Investigative Site

City

Tyler

State/Province

Texas

ZIP/Postal Code

75701

Country

United States

Facility Name

Kanghong Investigative Site

City

Willow Park

State/Province

Texas

ZIP/Postal Code

76087

Country

United States

Facility Name

Kanghong Investigative Site

City

Lynchburg

State/Province

Virginia

ZIP/Postal Code

24502

Country

United States

Facility Name

Kanghong Investigative Site

City

Norfolk

State/Province

Virginia

ZIP/Postal Code

23502

Country

United States

Facility Name

Kanghong Investigative Site

City

Warrenton

State/Province

Virginia

ZIP/Postal Code

20186

Country

United States

Facility Name

Kanghong Investigative Site

City

Silverdale

State/Province

Washington

ZIP/Postal Code

98383

Country

United States

Facility Name

Kanghong Investigative Site

City

Spokane

State/Province

Washington

ZIP/Postal Code

99204

Country

United States

Facility Name

Kanghong Investigative Site

City

Morgantown

State/Province

West Virginia

ZIP/Postal Code

26506

Country

United States

Facility Name

Kanghong Investigative Site

City

Caba

State/Province

Buenos Aires

ZIP/Postal Code

1120AAN

Country

Argentina

Facility Name

Kanghong Investigative Site

City

Caba

State/Province

Buenos Aires

ZIP/Postal Code

C1015ABO

Country

Argentina

Facility Name

Kanghong Investigative Site

City

Caba

State/Province

Buenos Aires

ZIP/Postal Code

C1023AAQ

Country

Argentina

Facility Name

Kanghong Investigative Site

City

Córdoba

State/Province

Cordoba

ZIP/Postal Code

X5000IIT

Country

Argentina

Facility Name

Kanghong Investigative Site

City

Rosario

State/Province

Santa Fe

ZIP/Postal Code

S2000AZH

Country

Argentina

Facility Name

Kanghong Investigative Site

City

Cordoba

ZIP/Postal Code

X5000AAJ

Country

Argentina

Facility Name

Kanghong Investigative Site

City

Mendoza

ZIP/Postal Code

M5500GGK

Country

Argentina

Facility Name

Kanghong Investigative Site

City

Albury

State/Province

New South Wales

ZIP/Postal Code

2640

Country

Australia

Facility Name

Kanghong Investigative Site

City

Liverpool

State/Province

New South Wales

ZIP/Postal Code

2170

Country

Australia

Facility Name

Kanghong Investigative Site

City

Parramatta

State/Province

New South Wales

ZIP/Postal Code

2150

Country

Australia

Facility Name

Kanghong Investigative Site

City

Strathfield

State/Province

New South Wales

ZIP/Postal Code

2135

Country

Australia

Facility Name

Kanghong Investigative Site

City

Sydney

State/Province

New South Wales

ZIP/Postal Code

2000

Country

Australia

Facility Name

Kanghong Investigative Site

City

Adelaide

State/Province

South Australia

ZIP/Postal Code

5000

Country

Australia

Facility Name

Kanghong Investigative Site

City

Glen Waverley

State/Province

Victoria

ZIP/Postal Code

3150

Country

Australia

Facility Name

Kanghong Investigative Site

City

Melbourne

State/Province

Victoria

ZIP/Postal Code

3002

Country

Australia

Facility Name

Kanghong Investigative Site

City

Crawley

ZIP/Postal Code

6009

Country

Australia

Facility Name

Kanghong Investigative Site

City

Sydney

ZIP/Postal Code

2000

Country

Australia

Facility Name

Kanghong Investigative Site

City

Feldkirch

State/Province

Hessen

ZIP/Postal Code

6800

Country

Austria

Facility Name

Kanghong Investigative Site

City

Klagenfurt am Wörthersee

ZIP/Postal Code

9020

Country

Austria

Facility Name

Kanghong Investigative Site in Linz

City

Linz

ZIP/Postal Code

4021

Country

Austria

Facility Name

Kanghong Investigative Site

City

Linz

ZIP/Postal Code

4021

Country

Austria

Facility Name

Kanghong Investigative Site

City

Vienna

ZIP/Postal Code

1090

Country

Austria

Facility Name

Kanghong Investigative Site

City

Vienna

ZIP/Postal Code

1130

Country

Austria

Facility Name

Kanghong Investigative Site

City

Laeken

ZIP/Postal Code

1020

Country

Belgium

Facility Name

Kanghong Investigative Site

City

Leuven

ZIP/Postal Code

B-3000

Country

Belgium

Facility Name

Kanghong Investigative Site

City

Calgary

State/Province

Alberta

ZIP/Postal Code

T2H 0C8

Country

Canada

Facility Name

Kanghong Ivestigative Site

City

Vancouver

State/Province

British Columbia

ZIP/Postal Code

V5Z 3N9

Country

Canada

Facility Name

Kanghong Investigative Site

City

London

State/Province

Ontario

ZIP/Postal Code

N6A 4G5

Country

Canada

Facility Name

Kanghong Investigative Site

City

Mississauga

State/Province

Ontario

ZIP/Postal Code

L4W 1W9

Country

Canada

Facility Name

Kanghong Investigative Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M3C 0G9

Country

Canada

Facility Name

Kanghong Investigative Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H4P 2S4

Country

Canada

Facility Name

Kanghong Investigative Site

City

Montréal

State/Province

Quebec

ZIP/Postal Code

H4A 3S5

Country

Canada

Facility Name

Kanghong Investigative Site

City

Sherbrooke

State/Province

Quebec

ZIP/Postal Code

J1G 2V4

Country

Canada

Facility Name

Kanghong Investigative Site

City

Santiago

State/Province

Region Metropolitana

ZIP/Postal Code

7500000

Country

Chile

Facility Name

Kanghong Investigative Site

City

Santiago

State/Province

Region Metropolitana

ZIP/Postal Code

7560994

Country

Chile

Facility Name

Kanghong Investigative Site

City

Barranquilla

State/Province

Atlantico

ZIP/Postal Code

080001

Country

Colombia

Facility Name

Kanghong Investigative Site

City

Bogotá

State/Province

Bogota

ZIP/Postal Code

110121

Country

Colombia

Facility Name

Kanghong Investigative Site

City

Cali

ZIP/Postal Code

760042

Country

Colombia

Facility Name

Kanghong Investigative Site

City

Medellin

ZIP/Postal Code

50016

Country

Colombia

Facility Name

Kanghong Investigative Site

City

Bonn

ZIP/Postal Code

53127

Country

Germany

Facility Name

Kanghong Investigative Site

City

Darmstadt

ZIP/Postal Code

64283

Country

Germany

Facility Name

Kanghong Investigative Site

City

Düsseldorf

ZIP/Postal Code

40549

Country

Germany

Facility Name

Kanghong Investigative Site

City

Frankfurt am Main

ZIP/Postal Code

60590

Country

Germany

Facility Name

Kanghong Investigative Site

City

Freiburg

ZIP/Postal Code

79106

Country

Germany

Facility Name

Kanghong Investigative Site

City

Göttingen

ZIP/Postal Code

37075

Country

Germany

Facility Name

Kanghong Investigative Site

City

Hannover

ZIP/Postal Code

30625

Country

Germany

Facility Name

Kanghong Investigative Site

City

Heidelberg

ZIP/Postal Code

69120

Country

Germany

Facility Name

Kanghong Investigative Site

City

Homburg

ZIP/Postal Code

66421

Country

Germany

Facility Name

Kanghong Investigative Site

City

Köln

ZIP/Postal Code

D-50937

Country

Germany

Facility Name

Kanghong Investigative Site

City

Leipzig

ZIP/Postal Code

4103

Country

Germany

Facility Name

Kanghong Investigative Site

City

Ludwigshafen

ZIP/Postal Code

67063

Country

Germany

Facility Name

Kanghong Investigative Site

City

Mainz

ZIP/Postal Code

55131

Country

Germany

Facility Name

Kanghong Investigative Site

City

Marburg

ZIP/Postal Code

35043

Country

Germany

Facility Name

Kanghong Investigative Site

City

Muenster

ZIP/Postal Code

48149

Country

Germany

Facility Name

Kanghong Investigative Site

City

München

ZIP/Postal Code

81675

Country

Germany

Facility Name

Kanghong Investigative Site

City

Regensburg

ZIP/Postal Code

93053

Country

Germany

Facility Name

Kanghong Investigative Site in Hong Kong

City

Hong Kong

ZIP/Postal Code

999077

Country

Hong Kong

Facility Name

Kanghong Investigative Site

City

Hong Kong

ZIP/Postal Code

999077

Country

Hong Kong

Facility Name

Kanghong Investigative Site

City

Kaunas

ZIP/Postal Code

LT-50161

Country

Lithuania

Facility Name

Kanghong Investigative Site

City

Vilnius

ZIP/Postal Code

LT-08661

Country

Lithuania

Facility Name

Kanghong Investigative Site

City

Jalisco

State/Province

Guadalajara

ZIP/Postal Code

44689

Country

Mexico

Facility Name

Kanghong Investigative Site

City

Jalisco

State/Province

Guadalajara

ZIP/Postal Code

45116

Country

Mexico

Facility Name

Kanghong Investigative Site

City

Rotterdam

State/Province

Zuid Holland

ZIP/Postal Code

3011 BH

Country

Netherlands

Facility Name

Kanghong Investigative Site

City

Amsterdam

ZIP/Postal Code

1105 AZ

Country

Netherlands

Facility Name

Kanghong Investigative Site

City

Tilburg

ZIP/Postal Code

5022GC

Country

Netherlands

Facility Name

Kanghong Investigative Site

City

Auckland

ZIP/Postal Code

1149

Country

New Zealand

Facility Name

Kanghong Investigative Site

City

Lima

ZIP/Postal Code

0000

Country

Peru

Facility Name

Kanghong Investigative Site

City

Lima

ZIP/Postal Code

15036

Country

Peru

Facility Name

Kanghong Investigator Site

City

Lima

ZIP/Postal Code

15036

Country

Peru

Facility Name

Kanghong Investigative Site

City

Lima

ZIP/Postal Code

15073

Country

Peru

Facility Name

Kanghong Investigative Site

City

Makati

State/Province

Manila

ZIP/Postal Code

1209

Country

Philippines

Facility Name

Kanghong Investigative Site

City

Pasig City

State/Province

Manila

ZIP/Postal Code

1600

Country

Philippines

Facility Name

Kanghong Investigative Site

City

Quezon City

State/Province

Manila

ZIP/Postal Code

1112

Country

Philippines

Facility Name

Kanghong Investigative Site

City

Kraków

State/Province

Lesser

ZIP/Postal Code

31-501

Country

Poland

Facility Name

Kanghong Investigative Site

City

Gdansk

ZIP/Postal Code

80-809

Country

Poland

Facility Name

Kanghong Investigative Site

City

Lodz

ZIP/Postal Code

91-134

Country

Poland

Facility Name

Kanghong Investigative Site

City

Lodz

ZIP/Postal Code

93-357

Country

Poland

Facility Name

Kanghong Investigative Site

City

Lublin

ZIP/Postal Code

Woj. Lubelskie 20-079

Country

Poland

Facility Name

Kanghong Investigative Site

City

Olsztyn

ZIP/Postal Code

10-424

Country

Poland

Facility Name

Kanghong Investigative Site

City

Wroclaw

ZIP/Postal Code

50-556

Country

Poland

Facility Name

Kanghong Investigative Site

City

Vila Franca de Xira

State/Province

Lisboa

ZIP/Postal Code

2600-009

Country

Portugal

Facility Name

Kanghong Investigative Site

City

Coimbra

ZIP/Postal Code

3000-075

Country

Portugal

Facility Name

Kanghong Investigative Site

City

Coimbra

ZIP/Postal Code

3000-548

Country

Portugal

Facility Name

Kanghong Investigative Site

City

Coimbra

ZIP/Postal Code

3030-163

Country

Portugal

Facility Name

Kanghong Investigative Site

City

Lisbon

ZIP/Postal Code

1050-085

Country

Portugal

Facility Name

Kanghong Investigative Site

City

Lisbon

ZIP/Postal Code

1649-035

Country

Portugal

Facility Name

Kanghong Investigative Site

City

Singapore

ZIP/Postal Code

119074

Country

Singapore

Facility Name

Kanghong Investigative Site

City

Sevilla

State/Province

Andalucia

ZIP/Postal Code

41009

Country

Spain

Facility Name

Kanghong Investigative Site

City

Barcelona

State/Province

Cataluna

ZIP/Postal Code

08907

Country

Spain

Facility Name

Kanghong Investigative Site

City

Barcelona

ZIP/Postal Code

08021

Country

Spain

Facility Name

Kanghong Investigative Site

City

Barcelona

ZIP/Postal Code

08028

Country

Spain

Facility Name

Kanghong Investigative Site

City

Barcelona

ZIP/Postal Code

08035

Country

Spain

Facility Name

Kanghong Investigatvie Site

City

Barcelona

ZIP/Postal Code

8024

Country

Spain

Facility Name

Kanghong Investigative Site

City

Bilbao

ZIP/Postal Code

48006

Country

Spain

Facility Name

Kanghong Investigative Site

City

Madrid

ZIP/Postal Code

28035

Country

Spain

Facility Name

Kanghong Investigative Site

City

Madrid

ZIP/Postal Code

28040

Country

Spain

Facility Name

Kanghong Investigative Site

City

Majadahonda

ZIP/Postal Code

28222

Country

Spain

Facility Name

Kanghong Investigative Site

City

Oviedo

ZIP/Postal Code

33012

Country

Spain

Facility Name

Kanghong Investigative Site

City

Pamplona

ZIP/Postal Code

31008

Country

Spain

Facility Name

Kanghong Investigative Site

City

Sant Cugat Del Vallès

ZIP/Postal Code

08195

Country

Spain

Facility Name

Kanghong Investigative Site

City

Santiago De Compostela

ZIP/Postal Code

15706

Country

Spain

Facility Name

Kanghong Investigative Site

City

Valencia

ZIP/Postal Code

46014

Country

Spain

Facility Name

Kanghong Investigative Site

City

Valencia

ZIP/Postal Code

46015

Country

Spain

Facility Name

Kanghong Investigative Site

City

Valladolid

ZIP/Postal Code

47012

Country

Spain

Facility Name

Kanghong Investigative Site in Zaragoza

City

Zaragoza

ZIP/Postal Code

50009

Country

Spain

Facility Name

Kanghong Investigative Site

City

Zaragoza

ZIP/Postal Code

50009

Country

Spain

Facility Name

Kanghong Investigative Site

City

Lausanne

State/Province

Canton De Vaud

ZIP/Postal Code

1000

Country

Switzerland

Facility Name

Kanghong Investigative Site

City

Bern

ZIP/Postal Code

3010

Country

Switzerland

Facility Name

Kanghong Investigative Site

City

Bern

ZIP/Postal Code

3012

Country

Switzerland

Facility Name

Kanghong Investigative Site

City

Zürich

ZIP/Postal Code

8063

Country

Switzerland

Facility Name

Kanghong Investigative Site

City

Zürich

ZIP/Postal Code

8091

Country

Switzerland

Facility Name

Kanghong Investigative Site

City

Changhua City

ZIP/Postal Code

500

Country

Taiwan

Facility Name

Kanghong Investigative Site

City

Taipei City

ZIP/Postal Code

10002

Country

Taiwan

Facility Name

Kanghong Investigative Site

City

Taipei City

ZIP/Postal Code

111

Country

Taiwan

Facility Name

Kanghong Investigative Site

City

Taipei city

ZIP/Postal Code

11217

Country

Taiwan

Facility Name

Kanghong Investigative Site

City

Taoyuan

ZIP/Postal Code

333

Country

Taiwan

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

We'll reach out to this number within 24 hrs

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

Neovascular Age-related Macular Degeneration

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial